FDA Must Grant Depomed's Pain Drug Exclusivity, Judge Says
A Washington, D.C., federal judge on Friday ordered the U.S. Food and Drug Administration to provide Depomed Inc. with seven years of exclusivity for its pain drug Gralise, finding the company...To view the full article, register now.
Already a subscriber? Click here to view full article